Table 3. Cytotoxicity of Complexes 1–8 under the Normoxic Conditions in Comparison to Cisplatin.
| IC50 (μM) ± S.D.a |
|||
|---|---|---|---|
| complex | PC3 | RPE-1 | selectivityb |
| 1 | 4.6 ± 0.5 | 0.36 ± 0.02 | |
| 2 | 5 ± 3 | 23 ± 2 | 5 |
| 3 | 0.32 ± 0.03 | 8.2 ± 0.4 | 26 |
| 4 | 0.04 ± 0.01 | 0.12 ± 0.01 | 3 |
| 5 | 0.03 ± 0.01 | 0.27 ± 0.02 | 9 |
| 6 | 0.05 ± 0.01 | 0.65 ± 0.03 | 13 |
| 7 | 1.4 ± 0.40 | 4.2 ± 0.5 | 3 |
| 8 | 0.41 ± 0.04 | 1.79 ± 0.04 | 4 |
| cisplatin | 6.9 ± 0.5 | 36 ± 4 | 5 |
a
S.D. is the standard deviation. The IC50 value was determined using the standard Resazurin assay after 48 h of treatment under normoxic conditions (∼15% O2 level). The representative plots are provided in Figures S29–S33.
b
Selectivity represents the ratio between IC50 against RPE-1 and IC50 against PC3 cells.